MedTrace Logo

Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III

NCT05886829 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2023-06-02

No results posted yet for this study

Summary

The goal of this clinical trial is to examine the effectiveness of intranasal-administered Chlorpheniramine Maleate in COVID-19-positive participants as part of early treatment for COVID-19. The main questions it aims to answer are:

* To assess the efficacy of nasal spray with Chlorpheniramine (0.4%) for improving clinical recovery in COVID-19 patients.
* To assess the efficacy, safety, and tolerability of nasal spray with Chlorpheniramine (0.4%) as an adjunct to the standard of care in reducing hospitalizations and improving clinical recovery in adult patients with mild COVID-19.

Conditions

  • COVID-19
  • Symptoms and Signs
  • COVID-19 Pandemic
  • Coronavirus Disease 2019
  • Coronavirus Infections

Interventions

COMBINATION_PRODUCT

Chlorpheniramine Maleate 0.4% Nasal Spray

Chlorpheniramine Maleate 0.4% Nasal Spray

COMBINATION_PRODUCT

Placebo

Placebo nasal spray

Sponsors & Collaborators

  • Hospital CEMESA Cortés, San Pedro Sula, Honduras

    collaborator UNKNOWN

  • Dr. Ferrer BioPharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-27
Primary Completion
2023-01-19
Completion
2023-02-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • Honduras

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05886829 on ClinicalTrials.gov